Novartis AG said it agreed to acquire Tourmaline Bio, Inc. at an offer price of $48 per share in cash, valuing the biopharmaceutical company at about $1.4 billion on a fully diluted basis.
www.bloomberg.com
#Novartis #Agrees #Buy #Tourmaline #Bio #Share #Cash
Novartis Agrees to Buy Tourmaline Bio for $48 Per Share in Cash
